EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance

Najyya Attia iD, Khalid Al Noaim iD, Manal Mustafa iD, Suliman H Al Fifi iD, Ibrahim Al Alwan iD, Nandu Thalange iD, Amir Babiker iD

Pediatric Diabetes · 2025-01 · 2025 (1)

DOI: 10.1155/pedi/6859764 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Diabetes, online erschienen am 20.12.2025. Verfasst von Najyya Attia und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia, ksau-hs.edu.sa. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Insulin Resistance, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control. Case Studies We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson–Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C‐peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2–4 years in these patients.

Conclusion

Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesInsulin ResistanceSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsHumansChildMaleFemaleAdolescentDiabetes Mellitus, Type 1Blood GlucoseChild, PreschoolTreatment Outcome

Stichwörter der Autor:innen

Rabson–Mendenhall syndromedapagliflozininsulin resistance type 1Asubcutaneous insulin resistancetype 1 diabetes mellitus

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia, ksau-hs.edu.sa.
  • Division of Pediatric Endocrinology, King Abdullah Specialized Children Hospital, King Abdulaziz Medical City, Jeddah, Saudi Arabia, ngha.med.sa.
  • Research Office, King Abdullah International Medical Research Centre, National Guard Health Affairs, Jeddah, Saudi Arabia, ngha.med.sa.
  • Department of Pediatrics, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia, kfu.edu.sa.
  • Division of Pediatric Endocrinology, Al Jalila Children's Speciality Hospital, Dubai, UAE, aljalilachildrens.ae.
  • Department of Child Health, College of Medicine, King Khalid University, Abha, Saudi Arabia, kku.edu.sa.

ORCID-Profile: Najyya Attia, Khalid Al Noaim, Manal Mustafa, Suliman H Al Fifi, Ibrahim Al Alwan, Nandu Thalange, Amir Babiker

Zitieren

APA

Attia, N., Al Noaim, K., Mustafa, M., Al Fifi, S. H., Al Alwan, I., Thalange, N., & Babiker, A. (2025). The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance. Pediatric Diabetes, 2025(1). https://doi.org/10.1155/pedi/6859764

Vancouver

Attia N, Al Noaim K, Mustafa M, Al Fifi SH, Al Alwan I, Thalange N, et al. The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance. Pediatric Diabetes. 2025;2025(1). doi:10.1155/pedi/6859764

BibTeX
@article{Attia2025,
  author = {Attia, Najyya and Al Noaim, Khalid and Mustafa, Manal and Al Fifi, Suliman H and Al Alwan, Ibrahim and Thalange, Nandu and Babiker, Amir},
  title = {The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance},
  journal = {Pediatric Diabetes},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/pedi/6859764}
}
Kostenlos starten →